Pharmaceutical company Neuraxpharm Group reported on Wednesday the formation of Neuraxpharm Portugal in Lisbon, expanding its operations in Southern Europe.
Neuraxpharm Portugal will be part of the company's Southern European Region that comprises Italy, Spain and now Portugal.
Through the new subsidiary, Neuraxpharm will leverage its industry networks and central nervous system (CNS) expertise to make its extensive portfolio available to patients. It is planning the first commercial launch in December this year with a probiotic product.
The company aims to build its position as a CNS specialist in Portugal offering its wide portfolio of branded and consumer healthcare products in the Portuguese market.
Javier Mercadé, the general manager of Italy and Spain, was appointed as head of Southern Region earlier this year and Teng Dias has been named as commercial director of the Neuraxpharm Portugal business.
Physiomics expands into biometrics with two contract wins and new division head
DELFI Diagnostics CTO receives 2025 Most Influential Women in Bay Area Business recognition
Healthcare Holding Schweiz AG acquires Effectum CH-Rep AG to expand services
iOncologi acquires TargImmune Therapeutics
Zydus enters exclusive talks to acquire majority stake in Amplitude Surgical
Adcendo's ADCE-T02 Phase I study IND application receives US FDA approval
WHO grants Actinogen Medical's Xanamem/UE2343 non-proprietary name 'emestedastat'
IVFMD physicians named 2025 Castle Connolly Top Doctors
HOPE Therapeutics and NRx Pharmaceuticals select BTIG as financial advisor
Partillion Bioscience opens pre-orders for Nanovial Multicell Assay Antibody Discovery Kits
Champions Oncology expands bioanalytical services with new technology
Petauri's Nicole Lodowski named to MM+M's 40 Under 40 for 2025